Mirum Pharmaceuticals Evaluates Livmarli in Long-Term Study for Alagille Syndrome and PFIC
Mirum Pharmaceuticals is conducting a long-term study to assess the safety and efficacy of Livmarli in patients with Alagille syndrome and PFIC.
Asset / Drug
Drug and asset intelligence for Livmarli with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.